LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Search

Ligand Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

200.01 -0.21

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

197.8

Максимум

207.35

Ключови измерители

By Trading Economics

Приходи

47M

4.8M

Продажби

70M

115M

P/E

Средно за сектора

92.606

105.69

Марж на печалбата

4.198

Служители

68

EBITDA

103M

62M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+18.65% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.5B

4.1B

Предишно отваряне

200.22

Предишно затваряне

200.01

Настроения в новините

By Acuity

28%

72%

70 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.11.2025 г., 18:59 ч. UTC

Значими двигатели на пазара

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17.11.2025 г., 23:40 ч. UTC

Пазарно говорене

Gold Consolidates Amid Mixed Signals -- Market Talk

17.11.2025 г., 23:34 ч. UTC

Пазарно говорене

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17.11.2025 г., 22:58 ч. UTC

Пазарно говорене

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17.11.2025 г., 22:46 ч. UTC

Пазарно говорене

Risk Assets Set to Have a Strong 2026 -- Market Talk

17.11.2025 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17.11.2025 г., 22:02 ч. UTC

Печалби

Trip.com Group 3Q Rev $2.6B >TCOM

17.11.2025 г., 22:02 ч. UTC

Печалби

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17.11.2025 г., 22:02 ч. UTC

Печалби

Trip.com Group 3Q EPS $4.02 >TCOM

17.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

17.11.2025 г., 21:40 ч. UTC

Печалби

James Hardie Industries 2Q Adj EPS 26c >JHX

17.11.2025 г., 21:40 ч. UTC

Печалби

James Hardie Industries 2Q Loss/Shr 10c >JHX

17.11.2025 г., 21:39 ч. UTC

Печалби

James Hardie Industries 2Q Sales $1.29B >JHX

17.11.2025 г., 21:38 ч. UTC

Печалби
Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17.11.2025 г., 21:38 ч. UTC

Печалби

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17.11.2025 г., 21:10 ч. UTC

Печалби

XP Inc. 3Q EPS BRL2.47 >XP

17.11.2025 г., 21:10 ч. UTC

Печалби

XP Inc. 3Q Rev BRL4.67B >XP

17.11.2025 г., 20:20 ч. UTC

Пазарно говорене

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17.11.2025 г., 20:12 ч. UTC

Пазарно говорене

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17.11.2025 г., 20:12 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.11.2025 г., 20:09 ч. UTC

Пазарно говорене

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17.11.2025 г., 19:29 ч. UTC

Пазарно говорене

Gold Slide Continues to Start Week -- Market Talk

17.11.2025 г., 19:16 ч. UTC

Печалби
Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17.11.2025 г., 18:20 ч. UTC

Придобивния, сливания и поглъщания

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17.11.2025 г., 16:45 ч. UTC

Придобивния, сливания и поглъщания

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17.11.2025 г., 16:16 ч. UTC

Печалби
Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17.11.2025 г., 16:15 ч. UTC

Печалби

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17.11.2025 г., 15:40 ч. UTC

Придобивния, сливания и поглъщания

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17.11.2025 г., 15:22 ч. UTC

Придобивния, сливания и поглъщания

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17.11.2025 г., 15:19 ч. UTC

Пазарно говорене

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ligand Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

18.65% нагоре

12-месечна прогноза

Среден 238.33 USD  18.65%

Висок 275 USD

Нисък 220 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Ligand Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

6

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

102.5 / 109.24Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Very Strong Bearish Evidence

Дългосрочен план

Weak Bullish Evidence

Настроение

By Acuity

70 / 374 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat